title: Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
abstract: BACKGROUND
  Because it is insufficiently clear whether BRCA-associated epithelial ovarian cancer (EOC) is more chemosensitive than sporadic EOC, we examined response to chemotherapy, progression-free survival (PFS) and overall survival (OS) in BRCA1- and BRCA2-associated versus sporadic EOC patients.
  
  
  METHODS
  Data about patient characteristics, response to and outcome after primary therapy, including chemotherapy, were collected from 99 BRCA1, 13 BRCA2 and 222 sporadic patients. Analyses were carried out using a chi-square test and Kaplan-Meier and Cox regression methods.
  
  
  RESULTS
  Complete response (CR) or no evidence of disease (NED) was observed in 87% of the BRCA1 patients, progressive disease (PD) in 2%, being 71% and 15%, respectively, in sporadic EOC patients (P = 0.002). In BRCA2 patients, 92% had CR/NED, and none PD (P = 0.27). Median PFS in BRCA1, BRCA2 and sporadic patients was 2.1 [95% confidence interval (CI) 1.9-2.5] years (P = 0.006), 5.6 (95% CI 0.0-11.5) years (P = 0.008) and 1.3 (95% CI 1.1-1.5) years, respectively. Median OS in the three groups was 5.9 (95% CI 4.7-7.0) years (P < 0.001), >10 years (P = 0.008), and 2.9 (95% CI 2.2-3.5) years, respectively. A trend for a longer PFS and OS in BRCA2 compared with BRCA1 patients was observed.
  
  
  CONCLUSIONS
  Compared with sporadic EOC patients, both BRCA1- and BRCA2-associated patients have improved outcomes after primary therapy, including chemotherapy.
authors.affiliation: Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Erasmus University Medical Center.
authors.forename: P M L H
authors.initials: PMLH
authors.lastname: Vencken
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center.
authors.forename: M
authors.initials: M
authors.lastname: Kriege
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center.
authors.forename: D
authors.initials: D
authors.lastname: Hoogwerf
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center.
authors.forename: S
authors.initials: S
authors.lastname: Beugelink
authors.affiliation: Department of Medical Oncology, Erasmus University Medical Center.
authors.forename: M E L
authors.initials: MEL
authors.lastname: van der Burg
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center.
authors.forename: M J
authors.initials: MJ
authors.lastname: Hooning
authors.affiliation: Department of Medical Oncology, Erasmus University Medical Center.
authors.forename: E M
authors.initials: EM
authors.lastname: Berns
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center.
authors.forename: A
authors.initials: A
authors.lastname: Jager
authors.affiliation: Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Collée
authors.affiliation: Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Erasmus University Medical Center.
authors.forename: C W
authors.initials: CW
authors.lastname: Burger
authors.affiliation: Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center-Daniel den Hoed Cancer Center. Electronic address: c.seynaeve@erasmusmc.nl.
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human